<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950647</url>
  </required_header>
  <id_info>
    <org_study_id>D2020109</org_study_id>
    <nct_id>NCT04950647</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nitrazine in the Treatment of ALS</brief_title>
  <official_title>Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the trend of safety and effectiveness of Nitroketazine tablets for ALS patients,&#xD;
      and to explore the best effective dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was a randomized, double-blind, placebo-controlled parallel design. Patients with&#xD;
      ALS were selected by inclusion exclusion criteria, and then randomly assigned to receive&#xD;
      either the experimental drug or placebo. Test group 1: Nitroketazine tablet 600mg group&#xD;
      (Nitroketazine 300mg tablet x2 + placebo 300mg tablet x2 each time; If the subject progresses&#xD;
      and cannot take 300 mg tablets, Nitroketazine 100mg tablets x6 tablets + placebo 100mg&#xD;
      tablets x6 tablets can be taken instead). Test group 2: Nitroketazine tablets 1200 mg group&#xD;
      (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take&#xD;
      300 mg tablets, Nitroketazine 100 mg tablets x12 tablets can be taken instead). Control&#xD;
      group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and&#xD;
      cannot take 300 mg tablets, they may take placebo 100mg tablets x 12 tablets instead). Usage:&#xD;
      Oral administration, twice a day, once in the morning and once in the evening (or the&#xD;
      interval between two medication is 28h), at least 1&quot; hour before meal (21 h before meal) on&#xD;
      an empty stomach or at least 2 hours after meal (22h after meal) on an empty stomach, 180±3&#xD;
      days. Eligible subjects will start treatment on Day 1 after randomization, and visit the&#xD;
      study center at the end of 1, 3, and 6 (or when they quit the study midway) for safety and&#xD;
      efficacy checks. Telephone interviews were conducted at the end of the seventh day of&#xD;
      treatment, the end of the second month, the end of the fourth month, the end of the fifth&#xD;
      month of treatment, and the second week after the end of the sixth month of treatment. A&#xD;
      total of 150 ALS patients were planned to be enrolled, with 50 patients in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALSFRS-R score</measure>
    <time_frame>Treatment day 180</time_frame>
    <description>ALSFRS -r score difference between the difference in value relative to the baseline group;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>grip strength</measure>
    <time_frame>Treatment day 180</time_frame>
    <description>Intergroup differences in grip strength relative to baseline difference</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Test group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitroketazine tablet 600 mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitroketazine tablets 1200 mg group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurazone Group 1</intervention_name>
    <description>Test group 1: Nitroketazine tablet 600 mg group (Nitroketazine 300 mg tablet X2 + placebo 300 mg tablet ×2 tablets each time; If the subject progresses and cannot take 300mg tablets, Nitroketazine 100mg tablets x6 + placebo 100mg tablets x6) can be replaced.</description>
    <arm_group_label>Test group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroketazine Group 2</intervention_name>
    <description>Test group 2: Nitroketazine tablets 1200 mg group (each oral Nitroketazine 300 mg tablets x4 tablets; If the subject progresses and cannot take 300 mg tablets, Nitroketazine 100mg tablets x12 tablets can be taken instead).</description>
    <arm_group_label>Test group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo group</intervention_name>
    <description>Control group: placebo group (placebo 300mg tablets x4 tablets each orally; If subjects progress and cannot take 300mg tablets, they may take placebo 100 mg tablets x 12 tablets instead).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 45-70, gender unlimited (including 45 and 70);&#xD;
&#xD;
          2. diagnoses in accordance with the confirmed and proposed ALS diagnostic standards ofthe&#xD;
             Revised World Federation of Neurology (1998);&#xD;
&#xD;
          3. The duration of disease from onset to randomization of subjects is less than 2 years;&#xD;
&#xD;
          4. Before randomization, ALSFRS-R scores were ≥2 points, and respiratory function items&#xD;
             were 4 points;&#xD;
&#xD;
          5. ALSFRS-R decreased by 1-4 points in screening period 3A (≥1 and lt; 4);&#xD;
&#xD;
          6. Random pre-respiratory function Forced Vital Capacity (%FVC) ≥80%;&#xD;
&#xD;
          7. Understand and abide by the test procedures, participate voluntarily, and sign the&#xD;
             informed consent (the informed consent should be signed by the person or the guardian&#xD;
             voluntarily).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Familial ALS (judged by family history);&#xD;
&#xD;
          2. Patients with significant cognitive impairment (MMSE: illiteracy group &amp;lt; 19 points,&#xD;
             elementary school. 22 points, S26 points in the junior high school and above group&#xD;
             (more than 8 years of education);&#xD;
&#xD;
          3. obvious dysphagia;&#xD;
&#xD;
          4. Severe renal insufficiency: creatinine clearance. 30 mL/min (Cockcroft-Gault formula),&#xD;
             or other known severe renal insufficiency;&#xD;
&#xD;
          5. Severe liver function impairment: ALT, AST&amp;GT; 3 times the upper limit of normal&#xD;
             value, or other known liver diseases such as acute or chronic active hepatitis,&#xD;
             cirrhosis, etc.;&#xD;
&#xD;
          6. In the screening stage, patients with heart failure who developed acute myocardial&#xD;
             infarction or underwent interventional therapy within the last 6 months (grade II1-IV&#xD;
             according to NYHA);&#xD;
&#xD;
          7. Complicated with malignant tumors, serious diseases of blood, digestion or other&#xD;
             systems.&#xD;
&#xD;
          8. Allergic to experimental drugs or ligustrazine;&#xD;
&#xD;
          9. Pregnancy and lactation;&#xD;
&#xD;
         10. Participated in, or is participating in, other clinical trials within 30 days prior to&#xD;
             screening;&#xD;
&#xD;
         11. The investigator did not consider it appropriate to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsheng Fan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongsheng Fan</last_name>
    <phone>+86 13701023871</phone>
    <email>dsfan@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100098</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrofurazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

